A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

Trial Profile

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Oprozomib (Primary) ; Midazolam
  • Indications Haematological malignancies; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Amgen
  • Most Recent Events

    • 14 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Oct 2017.
    • 10 Mar 2017 Planned End Date changed from 1 Apr 2017 to 1 Jul 2017.
    • 31 Jan 2017 Planned End Date changed from 1 Oct 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top